Acticor Biotech appoints Dr. Alain Munoz as Chairman of the Board of Directors

– FRANCE, Paris –  Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the appointment of Dr. Alain Munoz, MD, PhD as Chairman of the Board of Directors.

The company also announced the appointments of Sophie Binay and Yannick Pletan as General Managers. They will continue to assume their current functions in the company as CSO and CMO respectively.

“While finalizing the recruitment of our two phase 2 clinical trials in Acute Ischemic Stroke and in COVID-19 related ARDS, we are preparing the company for the next adaptive phase 2/3 clinical study in Acute Ischemic Stroke by strengthening our leadership team.” said CEO and founder, Gilles Avenard. “Alain, Sophie and Yannick are already key to Acticor Biotech success and I welcome them to their new positions”.

About Dr. Alain Munoz

Dr. Alain Munoz, MD, PhD, new Chairman of the Acticor Board of Directors, is a physician, qualified in cardiology and intensive care. He has over 30 years of experience in the industry at senior management level. He served as SVP for international development in the Sanofi Group and in the pharmaceutical division of Fournier Laboratories. He has been a member of the Scientific Committee of the French drug agency, Chairman of the Board of Hybrigenics SA and Novagali Pharma SA. He presently serves on the scientific advisory board of Valneva SA and in is an independent board member of Amryt Pharma plc, Auris Medical Holding AG and Zealand Pharma A/S.

“I am very enthusiastic to step in as Chairman of the Board and would like to thank all board members for their confidence and support to Acticor Biotech. Particular thanks to Gilles Avenard for the accomplishment in leading Acticor Biotech to this stage of clinical development in these unmet medical need indications” said Alain Munoz.

About Acticor Biotech

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke. Acticor Biotech is built upon the expertise and the results of research conducted by the founders: Dr. Martine Jandrot-Perrus at INSERM Paris and Pr. Philippe Billiald at Paris-Sud University.

Acticor Biotech is a partner in the BOOSTER consortium, dedicated to the management and new treatments of cerebrovascular accidents in emergency situations.

Acticor Biotech is backed by a syndicate of European and International investors: Karista, Go Capital, Newton Biocapital, CMS Ventures, Mirae Asset Capital, Anaxago, Primer Capital & Armesa Foundation.

For more information : https://acticor-biotech.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.